购物车
全部删除
您的购物车当前为空
别名 Icovamenib, BMF-219
Menin-MLL inhibitor 21 是一种选择性、口服、不可逆的 Menin 抑制剂。Menin-MLL inhibitor 21 可促进β细胞选择性增殖和体外人胰岛培养中 β 细胞功能的改善。Menin-MLL inhibitor 21 可增强动物糖尿病模型中的血糖控制。可诱导胰岛素分泌的剂量依赖性增强,并由 GLP-1 受体激动剂 (RA) 增强。


为众多的药物研发团队赋能,
让新药发现更简单!
Menin-MLL inhibitor 21 是一种选择性、口服、不可逆的 Menin 抑制剂。Menin-MLL inhibitor 21 可促进β细胞选择性增殖和体外人胰岛培养中 β 细胞功能的改善。Menin-MLL inhibitor 21 可增强动物糖尿病模型中的血糖控制。可诱导胰岛素分泌的剂量依赖性增强,并由 GLP-1 受体激动剂 (RA) 增强。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,430 | 现货 | |
| 5 mg | ¥ 3,150 | 现货 | |
| 10 mg | ¥ 4,970 | 现货 | |
| 25 mg | ¥ 7,570 | 现货 | |
| 50 mg | ¥ 9,870 | 现货 | |
| 100 mg | ¥ 13,700 | 现货 | |
| 200 mg | ¥ 18,500 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 3,930 | 现货 |
Menin-MLL inhibitor 21 相关产品
| 产品描述 | Menin-mll inhibitor 21 is a selective, oral and irreversible Menin inhibitor. Menin-MLL inhibitor 21 promotes selective proliferation of β cells and improvement of β cell function in human islet cultures in vitro. Menin-MLL inhibitor 21 enhances glycemic control in animal models of diabetes. Menin-MLL inhibitor 21 induced a dose-dependent increase in insulin secretion that was augmented by a GLP-1 receptor agonist (RA). |
| 别名 | Icovamenib, BMF-219 |
| 分子量 | 566.65 |
| 分子式 | C31H34N8O3 |
| CAS No. | 2448172-22-1 |
| Smiles | N(C(=O)C1=CC(CN2C[C@H](NC(C=C)=O)CCC2)=CC=N1)C3=CC=C(C4=CC5=C(N=CN=C5N4)N6CCOCC6)C=C3 |
| 密度 | no data available |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 50 mg/mL (88.24 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容